A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences. . . . → Read More: Immune Disease Biotech Acquired in $405M Deal
|
|||||
       
 |
 One comment - (Comments are closed)  Finance, New products  biomedical, biotechnology, chemistry, entrepreneurs, equity, investment, life sciences, merger, pharmaceuticals, physical sciences, U.K., university 
A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates. . . . → Read More: Ginkgo Acquires Biomaterials Maker as Industry Consolidates 
A developer of therapies derived from stem cells to replace malfunctioning islet cells in people with type 1 diabetes was acquired by Vertex Pharmaceuticals. . . . → Read More: Diabetes Cell Therapy Biotech Acquired in $320M Deal Comments are closed Finance, New products biomedical, biotechnology, equity, genomics, investment, life sciences, merger, pharmaceuticals, stem cells 
Drug maker GSK is buying a biotechnology company developing vaccines for respiratory and infectious diseases that generate multiple immune responses. . . . → Read More: GSK Acquires Advanced Vaccine Biotech in $3.3B Deal Comments are closed Finance, New products biomedical, biotechnology, chemistry, equity, investment, life sciences, merger, pharmaceuticals, physical sciences, U.K. 
A collaboration between developers of protein analytics and test-strip diagnostics aims to create a quicker, more sensitive, easy-to-use Covid-19 detection test. . . . → Read More: Partnership Developing Faster, Sensitive Covid-19 Test Comments are closed Joint ventures/collaborations, New products biomedical, biotechnology, cancer, chemistry, Covid-19, engineering, life sciences, medical device, merger, physical sciences, U.K. 
A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger Comments are closed Finance, New products biomedical, computer science, engineering, equity, investment, IPO, life sciences, mathematics, medical device, merger, physical sciences, software 
Global drug maker Novo Nordisk is acquiring biotechnology company Dicerna Pharmaceuticals Inc. in an all-cash deal valued at $3.3 billion. . . . → Read More: Novo Nordisk Buys RNA Biotech in $3.3B Deal Comments are closed Finance biomedical, biotechnology, equity, Europe, genomics, investment, life sciences, merger, pharmaceuticals 
A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, Europe, investment, IPO, merger, pharmaceuticals 
A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger Comments are closed Finance agriculture, biomedical, biotechnology, chemistry, Covid-19, entrepreneurs, equity, investment, IPO, life sciences, manufacturing, merger, physical sciences 
Drug maker Bayer is acquiring a company discovering new therapies with a technology that reveals complex protein targets considered difficult to address. . . . → Read More: Protein Chemistry Biotech Acquired in $2B Deal One comment - (Comments are closed) Finance biomedical, biotechnology, chemistry, entrepreneurs, Europe, investment, life sciences, merger, pharmaceuticals, physical sciences, preclinical |
|
|||
|
Copyright © 2022 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
